A First-in-Human Trial to Assess Safety and Early Effectiveness of LY4175408, an Antibody Drug Conjugate, in Participants With Selected Advanced Solid Tumors

What this Trial Is About

Researchers are evaluating the safety and preliminary effectiveness of LY4175408, an antibody drug conjugate, in people with selected advanced solid tumors such as non-small cell lung cancer, small cell lung cancer, endometrial cancer, and triple negative breast cancer. This Phase 1a/1b trial also studies how LY4175408 moves through and is processed by the body. Participation in the study could last up to 4 years. Participants receive LY4175408 through intravenous (IV) infusion, with doses adjusted during an initial escalation phase. Some participants may also receive pembrolizumab alone or combined with chemotherapy drugs carboplatin or cisplatin, all given by IV. The study includes several groups, such as dose escalation, dose optimization, and dose expansion cohorts, with treatments tailored based on disease status and prior therapies. During the study, participants undergo regular assessments including monitoring for dose-limiting toxicities, tumor response evaluations, and pharmacokinetic blood tests to measure drug levels. Researchers will track outcomes like overall response rate, progression-free survival, and duration of response up to about 4 years. Safety and tolerability are closely observed throughout the trial to understand LY4175408's effects over time.

A Study of LY4175408 in Participants With Advanced Cancer